摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴-3-氯溴苄 | 68120-44-5

中文名称
4-溴-3-氯溴苄
中文别名
2-氯-4-溴甲基溴苯
英文名称
1-bromo-4-(bromomethyl)-2-chlorobenzene
英文别名
——
4-溴-3-氯溴苄化学式
CAS
68120-44-5
化学式
C7H5Br2Cl
mdl
——
分子量
284.378
InChiKey
XCJXYTFYKPVYMK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2903999090

SDS

SDS:4a2af6d535f1ae2ccc33cb06756dfad3
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Bromo-3-chlorobenzyl bromide
Synonyms: 1-Bromo-4-bromomethyl-2-chlorobenzene

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-chlorobenzyl bromide
CAS number: 68120-44-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5Br2Cl
Molecular weight: 284.4

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents
    作者:Ana Flávia Borsoi、Josiane Delgado Paz、Bruno Lopes Abbadi、Fernanda Souza Macchi、Nathalia Sperotto、Kenia Pissinate、Raoní S. Rambo、Alessandro Silva Ramos、Diana Machado、Miguel Viveiros、Cristiano Valim Bizarro、Luiz Augusto Basso、Pablo Machado
    DOI:10.1016/j.ejmech.2020.112179
    日期:2020.4
    quinolines were synthesized and evaluated as in vitro inhibitors of Mycobacterium tuberculosis (M. tuberculosis) growth. Structure-activity relationship (SAR) studies leaded to potent antitubercular agents, with minimum inhibitory concentration (MIC) values as low as 0.3 μM against M. tuberculosis H37Rv reference strain. Furthermore, the lead compounds were active against multidrug-resistant strains
    使用经典的分子简化方法,合成了36种喹啉系列,并作为结核分枝杆菌(M. tuberculosis)生长的体外抑制剂进行了评估。结构-活性关系(SAR)研究导致了有效的抗结核药,针对结核分枝杆菌H37Rv参考菌株的最低抑菌浓度(MIC)值低至0.3μM。此外,先导化合物对多药耐药菌株具有活性,而与某些一线和二线药物没有交叉耐药性。对分子进行抗qcrB基因中单个突变的自发突变菌株的测试(T313A),表明合成的喹啉靶向细胞色素bc1复合物。此外,前体化合物对HepG2和Vero细胞没有明显的毒性,并且在人肝S9组分中显示出中等的消除率。最后,在结核感染的巨噬细胞模型中,选定的结构抑制了结核分枝杆菌的生长。综合来看,这些数据表明这类化合物可能为抗结核药物的未来发展提供候选。
  • Carbonylative Coupling of Alkyl Zinc Reagents with Benzyl Bromides Catalyzed by a Nickel/NN <sub>2</sub>  Pincer Ligand Complex
    作者:Thomas L. Andersen、Aske S. Donslund、Karoline T. Neumann、Troels Skrydstrup
    DOI:10.1002/anie.201710089
    日期:2018.1.15
    An efficient catalytic protocol for the three‐component assembly of benzyl bromides, carbon monoxide, and alkyl zinc reagents to give benzyl alkyl ketones is described, and represents the first nickelcatalyzed carbonylative coupling of two sp3‐carbon fragments. The method, which relies on the application of nickel complexed with an NN2‐type pincer ligand and a controlled release of CO gas from a solid
    描述了一种高效的催化方案,用于三组分组装苄基一氧化碳和烷基锌试剂,得到苄基烷基酮,它代表了两个sp 3-碳片段的第一个催化的羰基化偶联。该方法依赖于将与NN 2型钳形配位体配合使用,以及从固体前体中控制释放CO气体的方法,适用于一系列苄基化物。机理研究表明,以碳为中心的自由基是中间的。
  • [EN] 20-HETE FORMATION INHIBITORS<br/>[FR] INHIBITEURS DE FORMATION DE 20-HETE
    申请人:UNIV OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    公开号:WO2020163689A1
    公开(公告)日:2020-08-13
    This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.
    本公开提供了新颖的杂环化合物和抑制酶CYP4的方法。进一步公开的方法包括:一种抑制需要该物质的受试者体内20-羟基二十碳五烯酸(20-HETE)生物合成的方法,以及通过防止脑微血管血流受损和抗氧化机制来产生神经保护和减少脑损伤的方法,适用于正在经历或曾经经历缺血事件的受试者。
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    申请人:CHIESI FARMACEUTICI S.p.A
    公开号:US20140161736A1
    公开(公告)日:2014-06-12
    Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    本文件中描述的公式(I)化合物既可作为毒蕈碱受体拮抗剂,也可作为β2肾上腺素能受体激动剂,并且用于预防或治疗支气管阻塞或炎症性疾病。
  • CHEMICAL COMPOUNDS 785
    申请人:Birch Alan Martin
    公开号:US20100324068A1
    公开(公告)日:2010-12-23
    DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X 1 is linear (1-3C)alkyl; q is 0 or 1 and X 2 is fluoro, chloro or (1-3C)alkyl; Y 1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y 2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y 3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO 2 Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.
    DGAT-1抑制剂化合物公式(I),药物可接受的盐和前药,以及药物组合物、制造过程和使用方法,例如用于治疗肥胖 其中,例如,r为0或1,X 1 为线性(1-3C)烷基; q为0或1,X 2 为或(1-3C)烷基; Y 1 选自、(1-3C)烷基和(1-2C)烷氧基; n为0、1或2,Y 2 为或(1-3C)烷基; p为0、1或2,Y 3 为(1-3C)烷基或形成(3-5C)环烷基环; Z为羧基或—CONHSO 2 Me或—CONRbRc,其中Rb和Rc独立选自例如氢和(1-4C)烷基,或Rb和Rc相连以形成吗啉环或(4-6C)杂环,当Z为—CONRbRc时,Rb和Rc基团可以可选地被羧基取代。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫